fenofibrate has been researched along with Schizophrenia in 4 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Prenatal fenofibrate administration attenuated detrimental effects induced by MIA on both the schizophrenia-like behavioral phenotype and dopamine transmission in male offspring." | 7.91 | The PPARα agonist fenofibrate attenuates disruption of dopamine function in a maternal immune activation rat model of schizophrenia. ( Aroni, S; De Felice, M; Devoto, P; Fanni, S; Frau, R; Melis, M; Muntoni, AL; Pistis, M, 2019) |
| " Prenatal fenofibrate administration attenuated detrimental effects induced by MIA on both the schizophrenia-like behavioral phenotype and dopamine transmission in male offspring." | 3.91 | The PPARα agonist fenofibrate attenuates disruption of dopamine function in a maternal immune activation rat model of schizophrenia. ( Aroni, S; De Felice, M; Devoto, P; Fanni, S; Frau, R; Melis, M; Muntoni, AL; Pistis, M, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maekawa, M | 1 |
| Dadlani, N | 1 |
| Farrar, A | 1 |
| Jones, G | 1 |
| De Felice, M | 1 |
| Melis, M | 1 |
| Aroni, S | 1 |
| Muntoni, AL | 1 |
| Fanni, S | 1 |
| Frau, R | 1 |
| Devoto, P | 1 |
| Pistis, M | 1 |
| Landry, P | 1 |
| Dimitri, E | 1 |
| Tessier, S | 1 |
| Légaré, N | 1 |
4 other studies available for fenofibrate and Schizophrenia
| Article | Year |
|---|---|
[The nuclear receptor PPARα (peroxisome proliferator-activated receptor α) as a novel therapeutic target for schizophrenia].
Topics: Animals; Fenofibrate; Mice; PPAR alpha; Receptors, Cytoplasmic and Nuclear; Receptors, N-Methyl-D-As | 2023 |
Variability amongst urine toxicology amphetamine readings with concurrent administration of fenofibrate.
Topics: Adult; Amphetamine-Related Disorders; False Positive Reactions; Fenofibrate; Humans; Hypolipidemic A | 2018 |
The PPARα agonist fenofibrate attenuates disruption of dopamine function in a maternal immune activation rat model of schizophrenia.
Topics: Animals; Disease Models, Animal; Dopamine; Female; Fenofibrate; Male; Neuroimmunomodulation; Neurons | 2019 |
Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Atorvastatin; Cholesterol; Clozapine; Female; Fenofibrate; Gemfibrozil; | 2008 |